SCHEMBL8282072

SCHEMBL8282072

COc1ccc(C(=O)COc2ccc(CC3SC(=O)CC3=O)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 4/20 0.55
▸ MPC2 O95563 2/20 0.54
▸ CYP2C8 P10632 2/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ MAPT P10636 4/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ POLB P06746 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ BLM P54132 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ PLA2G4B P0C869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14213722 0.92 PPARG (0.56) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL8282081 0.89 PPARG (0.70) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL8282082 0.89 LMNA (0.53) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL14213573 0.89 PPARG (0.53) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL8282085 0.88 PPARG (0.66) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL14213724 0.86 PPARG (0.53) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL14213721 0.86 PPARG (0.50) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL14225794 0.85 PPARG (0.56) PPARGMPC2CYP2C8CYP2C9ALDH1A1
SCHEMBL14213723 0.84 PPARG (0.51) PPARGMPC2CYP2C8CYP2C9MAPT
SCHEMBL8282075 0.84 SMN1; SMN2 (0.54) PPARGMPC2CYP2C8CYP2C9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210825-A1 METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS CIRIUS THERAPEUTICS, INC. 2023-07-06 — — US disclosed
US-20160051529-A1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES CIRIUS THERAPEUTICS, INC. 2016-02-25 — — US disclosed
US-9126959-B2 PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) 2015-09-08 — — US disclosed
US-20150051406-A1 PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES CIRIUS THERAPEUTICS, INC. 2015-02-19 — — US disclosed
US-8912335-B2 PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) 2014-12-16 — — US disclosed
US-20130281414-A1 THIAZOLIDINEDIONE ANALOGUES METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) 2013-10-24 — — US disclosed
US-20130053350-A1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) 2013-02-28 — — US disclosed
US-20120322728-A1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) 2012-12-20 — — US disclosed
US-20120316138-A1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) 2012-12-13 — — US disclosed
US-20120309975-A1 PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) 2012-12-06 — — US disclosed
US-20120129896-A1 THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF METABOLIC DISEASES METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) 2012-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053350-A1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PPARD, PPARG, PPARA PPARG 2/4885MPC2 115/4885CYP2C8 2493/4885
US-20120309975-A1 PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES PPARD, PPARG, PPARA PPARG 2/4885MPC2 131/4885CYP2C8 1883/4885
US-20230210825-A1 METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS ACE, DPP4, ACE2 PPARG 19/4885MPC2 223/4885CYP2C8 548/4885
US-20150051406-A1 PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES PPARD, PPARG, PPARA PPARG 2/4885MPC2 131/4885CYP2C8 1883/4885
US-20160051529-A1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES PPARD, PPARG, PPARA PPARG 2/4885MPC2 85/4885CYP2C8 997/4885
US-20120316138-A1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES PPARD, PPARA, PPARG PPARG 3/4885MPC2 112/4885CYP2C8 385/4885
US-20130281414-A1 THIAZOLIDINEDIONE ANALOGUES FABP1, PPARD, FABP4 PPARG 4/4885MPC2 119/4885CYP2C8 722/4885
US-20120322728-A1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES GLP1R, PPARD, PPARA PPARG 4/4885MPC2 216/4885CYP2C8 1011/4885
US-20120129896-A1 THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF METABOLIC DISEASES PPARD, SLC5A2, SLC5A1 PPARG 4/4885MPC2 94/4885CYP2C8 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback